Biologic effects of dopamine on tumor vasculature in ovarian carcinoma

Neoplasia (United States)

Volumn 15, Issue 5, 2013, Pages 502-510

  Moreno Smith, Myrthala ^a   Lee, Sun Joo ^b   Chunhua, Lu ^a   Nagaraja, Archana S ^a   He, Guangan ^a   Rupaimoole, Rajesha ^a   Han, Hee Dong ^a   Jennings, Nicholas B ^a   Roh, Ju Won ^c   Nishimura, Masato ^d   Kang, Yu ^a   Allen, Julie K ^a   Armaiz, Guillermo N ^a   Matsuo, Koji ^a   Shahzad, Mian M K ^a   Bottsford Miller, Justin ^a   Langley, Robert R ^a   Cole, Steve W ^e   Lutgendorf, Susan K ^f   Siddik, Zahid H ^a   Sood, Anil K ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Konkuk University Hospital   (South Korea)

^c Dongguk University Ilsan Hospital   (South Korea)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; BETA ADRENERGIC RECEPTOR; BUTACLAMOL; CATECHOLAMINE; CD31 ANTIGEN; CISPLATIN; CYCLIC AMP; DOPAMINE; ETICLOPRIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZAZEPINE DERIVATIVE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; SK&F 82958;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CAPILLARY DENSITY; CELL MIGRATION; CHRONIC STRESS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EXPOSURE; ENZYME IMMUNOASSAY; FEMALE; HOUSEKEEPING GENE; IMMOBILIZATION STRESS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; ENDOTHELIUM CELL; HUMAN; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; OVARIAN NEOPLASMS; PHYSIOLOGICAL STRESS; PHYSIOLOGY; SECOND MESSENGER; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZAZEPINES; CATECHOLAMINES; CELL LINE, TUMOR; CISPLATIN; DOPAMINE; DOPAMINE AGENTS; DRUG SYNERGISM; ENDOTHELIAL CELLS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PERICYTES; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, DOPAMINE; SECOND MESSENGER SYSTEMS; STRESS, PHYSIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877049285     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121412     Document Type: Article

References (37)

1. Schmidt C and Kraft K (1996). Beta-endorphin and catecholamine concentrations during chronic and acute stress in intensive care patients. Eur J Med Res 1, 528-532.
2. Lutgendorf SK (2009). Depression, social support, and beta-adrenergic tran scription control in human ovarian cancer. Brain Behav Immun 23, 176-183.
3. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, et al. (2006). Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12, 939-944.
4. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, and Mukhopadhyay D (2001). The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7, 569-574.
5. Teunis MA, Kavelaars A, Voest E, Bakker JM, Ellenbroek BA, Cools AR, and Heijnen CJ (2002). Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J 16, 1465-1467.
6. Chakroborty D, Sarkar C, Basu B, Dasgupta PS, and Basu S (2009). Catecholamines regulate tumor angiogenesis. Cancer Res 69, 3727-3730.
7. Chakroborty D, Chowdhury UR, Sarkar C, Baral R, Dasgupta PS, and Basu S (2008). Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest 118, 1380-1389.
8. Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, et al. (2011). Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res 17, 3649-3659.
9. Chantrain CF, Henriet P, Jodele S, Emonard H, Feron O, Courtoy PJ, DeClerck YA, and Marbaix E (2006). Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases. Eur J Cancer 42, 310-318.
10. Buick RN, Pullano R, and Trent JM (1985). Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res 45, 3668-3676.
11. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, and Fidler IJ (1998). Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90, 447-454.
12. b -tsA58 mice for studies of angiogenesis and metastasis. Cancer Res 63, 2971-2976.
13. Verschraegen CF, Kumagai S, Davidson R, Feig B, Mansfield P, Lee SJ, Maclean DS, Hu W, Khokhar AR, and Siddik ZH (2003). Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol 129, 549-555.
14. Siddik ZH, Boxall FE, and Harrap KR (1987). Flameless atomic absorption spectrophotometric determination of platinum in tissues solubilized in hyamine hydroxide. Anal Biochem 163, 21-26.
15. -ΔΔCT method. Methods 25, 402-408.
16. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, and Cole SW (2006). Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12, 369-375.
17. Landen CN, Merritt WM, Mangala LS, Sanguino AM, Bucana C, Lu C, Lin YG, Han LY, Kamat AA, Schmandt R, et al. (2006). Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 5, 1708-1713.
18. Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, et al. (2006). Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 98, 1558-1570.
19. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, et al. (2013). Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun 4, 1403-1413.
20. Lu C and Sood AK (2008). Role of pericytes in angiogenesis. In Angiogenesis Agents in Cancer Therapy (2nd ed), BA Teicher and LM Ellis (Eds). Totowa, NJ, Humana Press, Inc. pp. 117-132.
21. Siddik ZH, Jones M, Boxall FE, and Harrap KR (1988). Comparative distribution and excretion of carboplatin and cisplatin in mice. Cancer Chemother Pharmacol 21, 19-24.
22. Jain RK (2003). Molecular regulation of vessel maturation. Nat Med 9, 685-693.
23. Fiedler U and Augustin HG (2006). Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol 27, 552-558.
24. Chakroborty D, Sarkar C, Yu H, Wang J, Liu Z, Dasgupta PS, and Basu S (2011). Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci USA 108, 20730-20735.
25. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
26. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, et al. (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563.
27. Xian X, Hakansson J, Stahlberg A, Lindblom P, Betsholtz C, Gerhardt H, and Semb H (2006). Pericytes limit tumor cell metastasis. J Clin Invest 116, 642-651.
28. Edelman AM, Blumenthal DK, and Krebs EG (1987). Protein serine/threonine kinases. Annu Rev Biochem 56, 567-613.
29. Gonzalez GA and Montminy MR (1989). Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59, 675-680.
30. Iyengar R (1996). Gating by cyclic AMP: expanded role for an old signaling pathway. Science 271, 461-463.
31. Lamb NJ, Fernandez A, Conti MA, Adelstein R, Glass DB, Welch WJ, and Feramisco JR (1988). Regulation of actin microfilament integrity in living nonmuscle cells by the cAMP-dependent protein kinase and the myosin light chain kinase. J Cell Biol 106, 1955-1971.
32. Yasumura Y, Buonassisi V, and Sato G (1966). Clonal analysis of differentiated function in animal cell cultures. I. Possible correlated maintenance of differentiated function and the diploid karyotype. Cancer Res 26, 529-535.
33. Schlaepfer DD, Hauck CR, and Sieg DJ (1999). Signaling through focal adhesion kinase. Prog Biophys Mol Biol 71, 435-478.
34. Schaller MD (2001). Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 1540, 1-21.
35. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, and Schlaepfer DD (2000). FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2, 249-256.
36. Frisch SM, Vuori K, Ruoslahti E, and Chan-Hui PY (1996). Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134, 793-799.
37. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD, and Hendrix MJ (2004). Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol 165, 1087-1095.